Ruo W. Steensma

Publications by Year

Research Areas

HIV Research and Treatment, HIV/AIDS drug development and treatment, Lung Cancer Treatments and Mutations, Chemical Synthesis and Analysis, Monoclonal and Polyclonal Antibodies Research

Most-Cited Works

• → Synthesis, Structure–Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials(2013)408 cited
• → Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK(2006)375 cited
• → Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. IV. Discovery of 1-[(4,6-Dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-{2-methoxy-1(R)-4-(trifluoromethyl)phenyl}ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a Potent, Highly Selective, and Orally Bioavailable CCR5 Antagonist(2004)136 cited
• → Piperazine-Based CCR5 Antagonists as HIV-1 Inhibitors. II. Discovery of 1-[(2,4-Dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoro- methyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-Oxide (Sch-350634), an Orally Bioavailable, Potent CCR5 Antagonist(2001)113 cited
• → Inhibition of the development of collagen‐induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5(2005)92 cited
• → Fragment-based discovery of JAK-2 inhibitors(2008)79 cited
• → Piperazine-Based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element(2001)65 cited
• → Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides(2003)52 cited
• → A novel method for the synthesis of aryl sulfones(2001)36 cited
• In vitro combination studies of Troxacitabine (Troxatyl™, SGX-145) against human tumor cell lines.(2006)